50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months
SAN ANTONIO, TX, USA I September 8, 2014 I GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company’s presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.
GenSpera presented a poster containing interim results from the Phase Ib and ongoing Phase II study in HCC patients who had previously progressed on, or who were intolerant of, sorafenib, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 50% of patients exhibited stable disease (no tumor growth) at 4 months on study.
“Mipsagargin is differentiated from most other drugs being tested in HCC due to its well-tolerated safety profile and the significant proportion of patients that experience prolonged disease stabilization while on treatment,” stated Dr. Craig Dionne, GenSpera CEO. “Liver cancer is the third largest cancer killer worldwide and is expected to represent a $1.5 billion market by 2019. We are encouraged by these early stage positive results and what they imply for our ongoing and planned Phase II clinical trials for mipsagargin in glioblastoma, prostate cancer and renal cell carcinoma patients.”
Investors can view the poster at the Company website: www.genspera.com
Rodman & Renshaw 16th Annual Global Investment Conference Details:
When: Tuesday, September 9th at 12:05 p.m. Eastern
Where: The New York Palace Hotel in New York City
About: www.rodm.com
To arrange a one-on-one meeting with management, please contact Steve Gersten at steve@capmarketsgroup.com.
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.
Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Company presentations are available at: www.genspera.com
Watch the Corporate Video: http://youtu.be/jULjEul-mBk
About ILCA 2014
The 8th Annual International Liver Cancer Association Conference was held September 5-7, 2014, at the Hotel Granvia Kyoto in Kyoto, Japan. The International Liver Cancer Association (ILCA) is an international organization devoted exclusively to liver cancer research for experts from all related disciplines. Visit the ILCA website at http://www.ilca2014.org.
SOURCE: GenSpera
Post Views: 206
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months
SAN ANTONIO, TX, USA I September 8, 2014 I GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company’s presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.
GenSpera presented a poster containing interim results from the Phase Ib and ongoing Phase II study in HCC patients who had previously progressed on, or who were intolerant of, sorafenib, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 50% of patients exhibited stable disease (no tumor growth) at 4 months on study.
“Mipsagargin is differentiated from most other drugs being tested in HCC due to its well-tolerated safety profile and the significant proportion of patients that experience prolonged disease stabilization while on treatment,” stated Dr. Craig Dionne, GenSpera CEO. “Liver cancer is the third largest cancer killer worldwide and is expected to represent a $1.5 billion market by 2019. We are encouraged by these early stage positive results and what they imply for our ongoing and planned Phase II clinical trials for mipsagargin in glioblastoma, prostate cancer and renal cell carcinoma patients.”
Investors can view the poster at the Company website: www.genspera.com
Rodman & Renshaw 16th Annual Global Investment Conference Details:
When: Tuesday, September 9th at 12:05 p.m. Eastern
Where: The New York Palace Hotel in New York City
About: www.rodm.com
To arrange a one-on-one meeting with management, please contact Steve Gersten at steve@capmarketsgroup.com.
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.
Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Company presentations are available at: www.genspera.com
Watch the Corporate Video: http://youtu.be/jULjEul-mBk
About ILCA 2014
The 8th Annual International Liver Cancer Association Conference was held September 5-7, 2014, at the Hotel Granvia Kyoto in Kyoto, Japan. The International Liver Cancer Association (ILCA) is an international organization devoted exclusively to liver cancer research for experts from all related disciplines. Visit the ILCA website at http://www.ilca2014.org.
SOURCE: GenSpera
Post Views: 206
